Mural Oncology plc Market Cap ($35.38 Million)
Market Cap & Net Worth: Mural Oncology plc (MURA)
Mural Oncology plc market cap. Mural Oncology plc (NASDAQ:MURA) has a market capitalization of $35.38 Million ($35.38 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22970 globally and #5041 in its home market, demonstrating a 0.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mural Oncology plc's stock price $2.04 by its total outstanding shares 17344486 (17.34 Million). Also see MURA operating cash flow for how efficiently the company converts equity into cash flow.
Mural Oncology plc Market Cap History (2023–2025)
Mural Oncology plc market cap history from 2023 to 2025. Data shows change from $102.68 Million to $35.38 Million (-26.00% CAGR). Check Mural Oncology plc (MURA) stock price for real-time trading data and today's change.
Index Memberships
Mural Oncology plc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #649 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2154 of 3165 |
Weight: Mural Oncology plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mural Oncology plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mural Oncology plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MURA shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MURA by Market Capitalization
Companies near Mural Oncology plc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Mural Oncology plc for a full breakdown of the balance sheet.
Key companies related to Mural Oncology plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Mural Oncology plc (2023–2025)
Market capitalization of Mural Oncology plc from 2023 to today. Between 2023 and today, Mural Oncology plc's market cap moved from $102.68 Million to $ 35.38 Million, with a yearly change of -26.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $35.38 Million | -36.65% |
| 2024 | $55.85 Million | -45.61% |
| 2023 | $102.68 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Mural Oncology plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.38 Million USD |
| MoneyControl | $35.38 Million USD |
| MarketWatch | $35.38 Million USD |
| marketcap.company | $35.38 Million USD |
| Reuters | $35.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more